Immunomodulation therapy - lenalidomide in the treatment of myelodysplastic syndrome in low-risk groups with deletion of the long arm of chromosome 5
2013
Abstract
Immunomodulation therapy is used to treat the cytogenetically most common subgroups of patients with MDS, specifically patients with the deletion of the long arm of chromosome 5, and is particularly effective in anaemic patients with 5q-syndrome. Lenalidomide is a thalidomide analogue with greater effect and without typical undesirable effects.
Its efficacy and safety has been confirmed in clinical studies, and we look back to our own experience in this indication.